Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
| Revenue (TTM) | $30.46B |
| Gross Profit (TTM) | $24.25B |
| EBITDA | $14.60B |
| Operating Margin | 33.70% |
| Return on Equity | -20.70% |
| Return on Assets | 14.10% |
| Revenue/Share (TTM) | $24.51 |
| Book Value | $9.53 |
| Price-to-Book | 16.00 |
| Price-to-Sales (TTM) | 6.14 |
| EV/Revenue | 6.97 |
| EV/EBITDA | 117.79 |
| Quarterly Earnings Growth (YoY) | 54.80% |
| Quarterly Revenue Growth (YoY) | 10.20% |
| Shares Outstanding | $1.24B |
| Float | $1.24B |
| % Insiders | 0.11% |
| % Institutions | 92.22% |
Volatility is currently contracting
The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP-1 weight loss drug manufacturers and midstream energy join the index, while battery technology & storage and software-as-a-service (SaaS) exit.
Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreements cover 120 high-incidence countries (which are primarily low- and lower-middle-income) and will support manufacturing readiness, technology transfer and future supply planning while the.
Gilead Sciences NASDAQ: GILD executives outlined plans to expand the company's HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O'Day describing the company as being at an “inflection point in value.”
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.42, denoting a +1.88% move from the preceding trading day.
Gilead Sciences NASDAQ: GILD CFO Andy Dickinson told attendees at the Cantor Global Healthcare Conference that the company sees continued growth opportunities across its HIV prevention and treatment businesses, while advancing programs in inflammation, oncology and cell therapy.
Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GILD and any ticker you trade — then tracks every position and per-strategy win rate.
